Trials / Completed
CompletedNCT03364049
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
Phase 1b Open-label Study of MK-7162 in Combination With Pembrolizumab (MK-3475) +/- Other Therapies in Participants With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-7162 | oral tablets |
| BIOLOGICAL | Pembrolizumab | IV infusion |
Timeline
- Start date
- 2017-12-06
- Primary completion
- 2020-10-19
- Completion
- 2020-10-19
- First posted
- 2017-12-06
- Last updated
- 2021-11-15
- Results posted
- 2021-11-15
Locations
6 sites across 4 countries: United States, Canada, Israel, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03364049. Inclusion in this directory is not an endorsement.